Edgewise Therapeutics Inc (EWTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $45.32 (-3.45%), Market cap $3.54B, 52-week low–high $12.61 ~ $38.01.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline o
Financial statements, price targets, institutional (13F) holdings and related news for Edgewise Therapeutics Inc are updated in real time on BlackAll Trade.
Edgewise Therapeutics Inc trades at $45.32 (-3.45%). Real-time quotes and charts are available on BlackAll Trade.
Edgewise Therapeutics Inc has a market cap of about $3.54B.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally adm